Skip to content

13F-HR filed by Sarissa Capital Management LP

Sarissa Capital Management LP filed this 13F-HR for the quarter ended 2022-09-30, filed 2022-11-14, with 11 holding rows worth $884,817,000.

Accession
0001567619-22-020094
Filed
2022-11-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2022

A holdings report, 11 entries on the cover page, a total value of $884,817,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $884,819,000 with VALUE read as thousands by filing date, 13F file number 028-15935. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ALKERMES PLCG01767105SHS14,040,000$313,513,000thousands by filing date
BIOGEN INC COM09062X103Stock643,000$171,681,000thousands by filing date
IRONWOOD PHARMACEUTICALS INC46333X108COMMON STOCK16,390,000$169,800,000thousands by filing date
Gilead Sciences,Inc.375558103COM1,273,100$78,538,000thousands by filing date
INNOVIVA INC45781M101COM6,614,000$76,789,000thousands by filing date
Mersana Therapeutics Inc59045L106Common Stock3,997,010$27,020,000thousands by filing date
AMARIN CORP PLC023111206SPONS ADR NEW23,998,000$26,158,000thousands by filing date
BIOCRYST PHARMACEUTICALS INC COM09058V103Stock1,390,790$17,524,000thousands by filing date
VOR BIOPHARMA INC929033108COM618,000$2,460,000thousands by filing date
PEAR THERAPEUTICS INC704723105COM500,356$1,021,000thousands by filing date
REGULUS THERAPEUTICS INC75915K309COM185,183$315,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001567619-22-020094this filing2022-11-14acceptance time not in the bulk data set